alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 10.4.2



 Exhibit 10.4.2 
 Confidential treatment requested under 17 C.F.R. §§ 200.80(b)(4) and 230.406. The confidential portions of this exhibit have been omitted and are marked accordingly. The confidential portions
have been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request. 

SECOND AMENDMENT TO AMENDED AND RESTATED 
 NERVE TISSUE PROCESSING AGREEMENT 
 THIS SECOND AMENDMENT (“Second
Amendment”) to the Amended and Restated Nerve Tissue Processing Agreement, dated as of February 27, 2008, as amended on June 27, 2008 (“Amendment”), entered into by and among LifeNet Health (“LifeNet”) and AxoGen
Corporation (the “Agreement”), is entered into between the parties on August 9, 2011 (“Effective Date”). 
 WHEREAS,
the parties wish to amend the Agreement under the terms and subject to the conditions set forth in this Second Amendment; 
 In consideration of
the mutual promises contained herein, the parties agree to the following: 
  

	 	1.	The parties agree that Appendix B to the Agreement is hereby deleted in its entirety and replaced with the attached Appendix B. 


 

	 	2.	The parties hereby agree that the fee schedule set forth in the attached amended Appendix B shall be retroactively effective to the last two operational weeks in
December 2010. 

  

	 	3.	This Second Amendment may be signed in any number of counterparts with the same effect as if the signatures thereto and hereto were upon the same instrument.


  

	 	4.	This Second Amendment was drafted by all parties concerned and thus any rule of contract interpretation calling for documents to be construed against the drafter shall
not apply to the construction of this Second Amendment. 

  

	 	5.	The Parties confirm and acknowledge that the Agreement is in full force and effect, that there have been no uncured events of breach to date, and that each represents
and warrants to the other that they are in material compliance with the Agreement. Except for the changes made by this Second Amendment to the Agreement and the Amendment, the Agreement remains in full force and effect without modification.


 IN WITNESS WHEREOF, the parties execute this Second Amendment as of the dates written below. 

 

									
	LIFENET HEALTH	  	 	  	AXOGEN CORPORATION
					
	By:	  	 /s/ Gordon Berkstresser
	  		  	By:	 	 /s/ John P. Engels

					
	Title:	  	 CFO
	  		  	Title:	 	 Vice President

					
	Date:	  	 08/10/11
	  		  	Date:	 	 08/10/11









 APPENDIX B 
 FEE SCHEDULE 
  

	 	1)	AXOGEN shall pay LIFENET HEALTH [**]. 

  

	 	2)	[**]. 

  

	 	3)	LIFENET HEALTH shall bill AXOGEN [**]. 

  

	 	4)	LIFENET HEALTH shall bill AXOGEN [**]. 


 

	**	Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment
Request.
<TABLE> <S> <C>

<ARTICLE> 9
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                        22536812
<INT-BEARING-DEPOSITS>                         2504343
<FED-FUNDS-SOLD>                               9200000
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                   79301086
<INVESTMENTS-CARRYING>                               0
<INVESTMENTS-MARKET>                                 0
<LOANS>                                      326084412
<ALLOWANCE>                                    2395536
<TOTAL-ASSETS>                               466954419
<DEPOSITS>                                   420954419
<SHORT-TERM>                                   3217611
<LIABILITIES-OTHER>                            4209174
<LONG-TERM>                                    8061164
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        200484
<OTHER-SE>                                    31223168
<TOTAL-LIABILITIES-AND-EQUITY>               466954419
<INTEREST-LOAN>                                7781363
<INTEREST-INVEST>                              1299149
<INTEREST-OTHER>                                 39603
<INTEREST-TOTAL>                               9120115
<INTEREST-DEPOSIT>                             4442298
<INTEREST-EXPENSE>                             4642601
<INTEREST-INCOME-NET>                          4477514
<LOAN-LOSSES>                                   197978
<SECURITIES-GAINS>                              (2590)
<EXPENSE-OTHER>                                4300710
<INCOME-PRETAX>                                1154090
<INCOME-PRE-EXTRAORDINARY>                      822186
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    822186
<EPS-PRIMARY>                                     0.42
<EPS-DILUTED>                                     0.42
<YIELD-ACTUAL>                                    4.43
<LOANS-NON>                                     671000
<LOANS-PAST>                                    526000
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                               2424847
<CHARGE-OFFS>                                   256011
<RECOVERIES>                                     28722
<ALLOWANCE-CLOSE>                              2395536
<ALLOWANCE-DOMESTIC>                           2395536
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        

</TABLE>
Teresa Cristina Alencar SILVA, Appellant, v. Benjamin U. JACKSON, Appellee.

Case No. 2D17-343

District Court of Appeal of Florida, Second District.

Opinion filed November 3, 2017

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE 
CONSOLIDATED BALANCE SHEET AS OF DECEMBER 31, 1997 AND CONSOLIDATED STATEMENT
OF OPERATIONS FOR THE PERIOD ENDED JULY 15, 1998.
</LEGEND>
<CIK>                         0000750274
<NAME>                        Buffets, Inc.
<MULTIPLIER>                                   1,000
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                              DEC-30-1998
<PERIOD-START>                                 JAN-01-1998
<PERIOD-END>                                   JUL-15-1998
<CASH>                                              79,977
<SECURITIES>                                             0
<RECEIVABLES>                                        1,358
<ALLOWANCES>                                             0
<INVENTORY>                                          3,971
<CURRENT-ASSETS>                                   101,994
<PP&E>                                             517,537
<DEPRECIATION>                                     187,701
<TOTAL-ASSETS>                                     442,702
<CURRENT-LIABILITIES>                              101,671
<BONDS>                                             43,272
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                               457
<OTHER-SE>                                         290,780
<TOTAL-LIABILITY-AND-EQUITY>                       442,702
<SALES>                                            461,408
<TOTAL-REVENUES>                                   461,408
<CGS>                                              395,556
<TOTAL-COSTS>                                      395,556
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                   1,854
<INCOME-PRETAX>                                     34,894
<INCOME-TAX>                                        13,435
<INCOME-CONTINUING>                                 21,459
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                        21,459
<EPS-PRIMARY>                                          .47
<EPS-DILUTED>                                          .45
        



</TABLE>
Exhibit 10.42

 

AMENDMENT #4

 

To Letter of Intent for Proposed CRADA #2166

 

“Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent”

 

The purpose of this Amendment is to change certain terms of the Letter of Intent (LOI) for the proposed Cooperative Research and Development Agreement (CRADA) entitled “Preclinical and Clinical Development of  1-Methyl [d]-Tryptophan as an Anticancer Agent.” These changes are reflected below, and except for these changes, all other provisions of the original CRADA LOI remain in full force and effect. Two originals of this Amendment are provided for execution; one is to remain with the National Cancer Institute (NCI) and the other original is to remain with the Collaborator.

 

Upon final signature, the term of the CRADA Letter of Intent is extended for six months from May 23, 2009 to November 23, 2009.

 

 

	
ACCEPTED AND AGREED TO:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
For the National Cancer Institute:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/Anna D. Barker
    	
 
    	
10/16/09
    	
 
    
	
Anna D. Barker, Ph.D.
    	
 
    	
Date
    
	
Deputy Director, NCI
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
For NewLink Genetics Corporation:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/Nicholas Vahanian
    	
 
    	
10/28/09
    	
 
    
	
Nicholas Vahanian
    	
 
    	
Date
    
	
Chief Operating Officer
<TABLE> <S> <C>


        <S> <C>

<ARTICLE> 5

<S>                                       <C>
<PERIOD-TYPE>                           3-MOS
<FISCAL-YEAR-END>                 DEC-31-1996
<PERIOD-END>                      SEP-30-1996
<CASH>                                 43,539
<SECURITIES>                                0
<RECEIVABLES>                          45,700
<ALLOWANCES>                                0
<INVENTORY>                                 0
<CURRENT-ASSETS>                      104,064
<PP&E>                                 72,082
<DEPRECIATION>                         12,544
<TOTAL-ASSETS>                        294,969
<CURRENT-LIABILITIES>                 608,052
<BONDS>                                     0
<PREFERRED-MANDATORY>                       0
<PREFERRED>                                 0
<COMMON>                            5,971,733
<OTHER-SE>                        (6,603,865)
<TOTAL-LIABILITY-AND-EQUITY>          294,969
<SALES>                                     0
<TOTAL-REVENUES>                            0
<CGS>                                       0
<TOTAL-COSTS>                         187,488
<OTHER-EXPENSES>                            0
<LOSS-PROVISION>                            0
<INTEREST-EXPENSE>                     10,225
<INCOME-PRETAX>                     (197,713)
<INCOME-TAX>                                0
<INCOME-CONTINUING>                         0
<DISCONTINUED>                              0
<EXTRAORDINARY>                             0
<CHANGES>                                   0
<NET-INCOME>                        (197,713)
<EPS-PRIMARY>                           (.01)
<EPS-DILUTED>                           (.01)




</TABLE>
Fourth Court of Appeals

San Antonio, Texas

December 20, 2016

No. 04-16-00452-CR

Jose Guadalupe AGUIRRE,

Appellant

v.

The STATE of Texas,

Appellee

From the 144th Judicial District Court, Bexar County, Texas

Trial Court No. 2015CR7206

Honorable Lorina I. Rummel, Judge Presiding

O R D E R

Appellant’s unopposed motion to file amended opening brief is granted. The appellee’s 

brief is due January 16, 2017.

_________________________________

Sandee Bryan Marion, Chief Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 20th day of December, 2016.

___________________________________

Keith E. Hottle

Clerk of Court
Document

DIAMOND HILL INVESTMENT GROUP, INC.
COMPENSATION RECOUPMENT AND RESTITUTION POLICY ACKNOWLEDGMENT


I acknowledge receipt of the Diamond Hill Investment Group, Inc. Compensation Recoupment and Restitution Policy ("Policy"). I have read and understand the Policy and have had the opportunity to ask questions to the Company regarding the Policy.


I also understand and acknowledge that:


1.The Policy shall apply to any and all cash and stock-based awards, deferred compensation, performance-based compensation and other forms of cash or equity incentive compensation (collectively, "Awards") and that all such Awards are subject to adjustment or recoupment under the Policy.


2.The recoupment or restitution of Awards pursuant to the Policy will not in any way limit or affect the Company's right to pursue disciplinary action or dismissal, take legal action or pursue any other available remedies available to the Company.


3.The Company, in its sole discretion, may amend or restate the Policy from time to time after the date of this acknowledgment, and the Policy, as amended or restated, will apply to all Awards after the date of this acknowledgment. The Company will provide to me a copy of the Policy as it may be amended or restated.




			
	DIAMOND HILL INVESTMENT GROUP, INC.




Employee:
<TABLE> <S> <C>

                  <ARTICLE>                                           5

                  <S>                                    <C>
                  <PERIOD-TYPE>                                   3-MOS
                  <FISCAL-YEAR-END>                         DEC-31-1999
                  <PERIOD-END>                              JUN-30-1999
                  <CASH>                                        325,038
                  <SECURITIES>                                        0
                  <RECEIVABLES>                               2,078,729
                  <ALLOWANCES>                                 (38,171)
                  <INVENTORY>                                 3,742,681
                  <CURRENT-ASSETS>                            6,584,302
                  <PP&E>                                      6,191,425
                  <DEPRECIATION>                              2,517,343
                  <TOTAL-ASSETS>                             10,551,776
                  <CURRENT-LIABILITIES>                       5,893,053
                  <BONDS>                                             0
                  <PREFERRED-MANDATORY>                               0
                  <PREFERRED>                                         0
                  <COMMON>                                       34,985
                  <OTHER-SE>                                  2,705,078
                  <TOTAL-LIABILITY-AND-EQUITY>               10,551,776
                  <SALES>                                     3,690,094
                  <TOTAL-REVENUES>                            3,690,094
                  <CGS>                                       2,169,199
                  <TOTAL-COSTS>                               3,825,277
                  <OTHER-EXPENSES>                              272,632
                  <LOSS-PROVISION>                                    0
                  <INTEREST-EXPENSE>                            272,555
                  <INCOME-PRETAX>                             (407,815)
                  <INCOME-TAX>                                        0
                  <INCOME-CONTINUING>                         (407,815)
                  <DISCONTINUED>                                      0
                  <EXTRAORDINARY>                                     0
                  <CHANGES>                                           0
                  <NET-INCOME>                                (407,815)
                  <EPS-BASIC>                                  (0.12)
                  <EPS-DILUTED>                                  (0.12)


</TABLE>
----

----

|  | (1) | The                  report fully complies with the requirements of section 13(a) or                  15(d) of                  the Securities Exchange Act of 1934;                  and |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (2) | The                  information contained in the report fairly presents, in all material                  respects, the financial condition and results of operations of                  the                  Company. |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Dated:   September                  28, 2007 | By:    | /s/                  BRUCE                  STEPHENS             |
|-------------------------------------------------------------|--------|------------------------------------------------------------------------------------------------------------------------------|
|                                                        |   | Bruce                  Stephens                                                                                              |
|                                                        |   | Chief                  Executive Officer and                                                                                 |
|                                                        |   | Principal                  Accounting Officer                                                                                |

----
T.C.W., a child, Appellant, v. STATE of Florida, Appellee.

Nos. 4D17-770 4D17-771

District Court of Appeal of Florida, Fourth District.

[February 1, 2018]

**DECISION WITHOUT PUBLISHED OPINION**

*Affirmed.*
September 9, 2009

Ms. Margaret Gilligan Associate Administratorfor Aviation Safety Aviation Safety Federal Aviation Administration 800 Independence Avenue SW. Washington, DC 20571 DearMs. Gilligan: On behalfofthe Flight and Duty Time Limitations and Rest Requirements Aviation Rulemaking Committee (ARC), we are pleasedto provide you with a copy ofthe ARC's recommendations onupdated flight and duty time limitations and rest requirements. The recommendations are in the format ofa draft notice ofproposed rulemaking, as required by the ARC's charter. These recommendations reflect diligent work by the ARC on an accelerated timeline, and represent careful deliberation bythe members, combining the best available science and their collective experience in the air carrier industry. We are confidentthat the recommendations represent a substantial improvement over current regulations and will be effective inhelping to achieve the FAA's goal ofreducing fatigue and increasing alertness among flightcrew members. We trustthese recommendations will be helpful in your decisionrnaking process. We and our fellow ARC members standready to assist the FAA in prioritizing implementation of the ARC'srecommendations. Sincerely,

Enclosure Don Wykoff Co-Chair
# Official Journal L 4/2011

| | ISSN 1725-2555
  doi:10.3000/17252555.L_2011.004.eng |
| --- | --- |
| Official Journal
  of the European Union | L 4 |
| | |
| English edition | Legislation | Volume 547 January 2011 |

ISSN 1725-2555

doi:10.3000/17252555.L_2011.004.eng

Official Journal

of the European Union

L 4

English edition

Legislation

Volume 547 January 2011

---

| Contents | | II   Non-legislative acts | page |
| --- | --- | --- | --- |
| | | REGULATIONS |
| | | Commission Regulation (EU) No 7/2011 of 6 January 2011 establishing the standard import values for determining the entry price of certain fruit and vegetables | 1 |
| | | Commission Regulation (EU) No 8/2011 of 6 January 2011 amending the representative prices and additional import duties for certain products in the sugar sector fixed by Regulation (EU) No 867/2010 for the 2010/11 marketing year | 3 |
| | | Commission Regulation (EU) No 9/2011 of 6 January 2011 fixing the minimum selling price for skimmed milk powder for the 13th individual invitation to tender within the tendering procedure opened by Regulation (EU) No 447/2010 | 5 |

Contents

II   Non-legislative acts

page

REGULATIONS

Commission Regulation (EU) No 7/2011 of 6 January 2011 establishing the standard import values for determining the entry price of certain fruit and vegetables

1

Commission Regulation (EU) No 8/2011 of 6 January 2011 amending the representative prices and additional import duties for certain products in the sugar sector fixed by Regulation (EU) No 867/2010 for the 2010/11 marketing year

3

Commission Regulation (EU) No 9/2011 of 6 January 2011 fixing the minimum selling price for skimmed milk powder for the 13th individual invitation to tender within the tendering procedure opened by Regulation (EU) No 447/2010

5

| EN | Acts whose titles are printed in light type are those relating to day-to-day management of agricultural matters, and are generally valid for a limited period.
  The titles of all other Acts are printed in bold type and preceded by an asterisk. |
| --- | --- |

EN

Acts whose titles are printed in light type are those relating to day-to-day management of agricultural matters, and are generally valid for a limited period.

The titles of all other Acts are printed in bold type and preceded by an asterisk.